Year: 2020

23
September 2020
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
Read more
09
September 2020
First patient dosed in a phase 1/2 trial with EO2401, an innovative ‘OncoMimic’ based immunotherapy candidate targeting adrenal tumors
Read more
03
August 2020
Enterome scientists contribute to extensive new genomic and proteomic catalog to enhance analysis of the gut microbiome and understanding of its role in human health
Read more
30
July 2020
Enterome initiates first clinical trial with EO2401 – an innovative microbiome-antigen (‘OncoMimic’) based cancer immunotherapy candidate targeting aggressive brain cancer
Read more
25
June 2020
Enterome completes €46.3 million ($52.6 million) financing to progress the clinical development of its therapeutic pipeline
Read more
03
February 2020
Enterome collaborates with BIOASTER Institute to provide new insights into mechanisms of potential microbiome-derived cancer immunotherapies
Read more

Enterome France

Headquarters
94/96 avenue Ledru-Rollin 75011 Paris – France
Tel: +33 (0)1 75 77 27 85
Lab facilities
Biocluster Genopole
5 rue Henri Desbruères – 91030 Evry Cedex